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SUMMARY
The European Sero-Epidemiology Network 2 (ESEN2) aimed to compare serological results of
vaccine-preventable diseases across Europe. To ensure direct inter-country comparability of
hepatitis A virus antibody (anti-HAV) measurements, a standardization panel of 150 sera was
developed by a designated reference laboratory and tested by participating national laboratories
using assays of choice; each country’s results were subsequently regressed against those of the
reference laboratory. Quantitatively, the assays were generally highly correlated (R2>0.90).
Nevertheless, qualitative comparisons indicated that results obtained with different assays may
differ despite the usage of well-established international and local standards. To a great extent
standardization successfully alleviated such differences. The generated standardization equations
will be used to convert national serological results into common units to enable direct international
comparisons of HAV seroprevalence data. The results of this study are expected to contribute to
the evaluation and potential improvement of the currently employed immunization strategies for
hepatitis in Europe.
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INTRODUCTION
Hepatitis A virus (HAV) that is enterically trans-
mitted, typically causes a mild, self-limited disease
leading to life-long immunity. However, clinical
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symptoms are more frequent and more severe with
increased age at infection; furthermore, in the case
of underlying chronic hepatic burden due to hepatitis
B or C viruses (HBV and HCV, respectively), super-
infection with HAV may result in fulminant hepatitis
[1–4]. Therefore, HAV infections are still of public
health importance in the Western world. Travelling
to highly endemic regions without having received
the recommended immune prophylaxis constitutes a
considerable risk factor of infection with HAV (re-
viewed in Franco et al. [5]), especially in backpackers
and foreign-aid volunteers [6].
Large-scale screening for antibodies to hepatitis
A virus (anti-HAV) using various techniques in the
late 1970s has provided significant insights into the
epidemiology of the infection [7–10]. More recent
studies report a decline in the anti-HAV sero-
prevalence in most parts of the developed world that
may be generally accounted for by improvements in
socioeconomic and hygienic conditions and, in some
instances, by the application of effective vaccination
(reviewed in Jacobsen & Koopman [11]). This re-
markable decline in HAV exposure rates particularly
during childhood has resulted in a shift of the infec-
tion to adulthood, where symptoms are more severe.
Serological monitoring is essential to the design and
evaluation of effective vaccination programmes; this
is particularly true for HAV infections that are no-
toriously under-reported [11]. Seroprevalence studies
of several vaccine-preventable diseases have been
performed recently in countries participating in the
European Sero-Epidemiology Network (ESEN) pro-
jects. The original ESEN project, which was estab-
lished in 1996, aimed to coordinate and harmonize the
serological surveillance of immunity to five vaccine-
preventable diseases (measles, mumps, rubella, per-
tussis and diphtheria) in eight European countries
[12]. ESEN2 followed in 2001 and included three ad-
ditional infections [varicella zoster virus (VZV) and
hepatitis A and B] and further participant countries
[13]. In each case, national banks of several thousand
age- and sex-stratified sera, termed ‘main serum
banks’, were collected and tested using enzyme
immunoassays (EIAs) for antibodies to the various
antigens by a national laboratory.
Comparison of these seroprevalence data, generated
at different national laboratories using diverse EIAs,
depends upon the comparability of exchanged infor-
mation [14]. However, inter-laboratory variation, even
when using the same EIA and international standards,
is a well-recognized problem [15–21] ; accordingly,
differences mostly in sensitivity, but also in specificity,
have been reported for both commercial and in-house
anti-HAV assays [22–31]. Standardization is a metho-
dological approach that provides ameans to overcome
this limitation and to ensure the direct comparability
of seroepidemiological results obtained during the
project [32].
Herein, we describe the process of standardization
for anti-HAV antibodies obtained in 15 countries
across Europe, which was accomplished using a panel
of sera that was prepared by a designated reference
laboratory and tested by all participant national
laboratories. Standardization equations were then
generated by regressing each country’s panel results
against the results of the reference laboratory. Using
these equations it is possible to transform each coun-
try’s national results into common units and, hence,




The methodology was based on that developed in
the original ESEN project [12]) and is described in
detail by Kafatos et al. [32]. Briefly, for each antigen,
a reference laboratory was selected, with the re-
sponsibility of constructing and distributing to the
other participant countries a special panel of sera,
‘ the standardization panel ’, that included known
negative, low-positive and positive specimens. The
standardization panel was then tested by each
national laboratory with their established assay and
this same assay was used to test the national banks of
serum specimens collected in each country, the main
serum banks. The quantitative results of antibody
testing for each antigen from each country were re-
gressed or calibrated against those of the reference
country by the Health Protection Agency, Centre for
Infections, London, and standardization equations
were derived, enabling the conversion of the results of
the participating countries to the units of the reference
laboratory.
Within the framework of ESEN2, the Hellenic
Centre for Infectious Diseases Control (HCIDC) re-
presented by the National Retrovirus Reference
Centre, Department of Hygiene and Epidemiology,
University of Athens Medical School in Athens,
Greece served as the reference laboratory for hepatitis
A and was, therefore, responsible for the development
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of the standardization panel of samples. The panel
was distributed to all participating national lab-
oratories that were to test it for total anti-HAV
antibodies with an assay of their choice, according
to standard operating procedures, on two occasions:
first, at the beginning of the project to evaluate the
performance of the assays in comparison to the
assay used by the reference laboratory, and, second,
during the testing of the main serum bank in order
to control for any assay drift. On the same two occa-
sions, the standardization panel was tested twice at
the reference laboratory to minimize between-test
variability while calculating mean values of antibody
titres.
An alternative method termed ‘back-standardiz-
ation’ was undertaken by countries whose main serum
banks had already been tested prior to the distribution
of the standardization panel [32]. In addition to the
testing of the panel with the country’s established as-
say at the national laboratory, this procedure entailed
the testing of a subset of about 150 titre-stratified
(negative, low-positive, and positive) samples from
the country’s main serum bank at the reference
laboratory with its chosen assay. Standardization was
then performed in the same way as before, while
taking into account the results of both the stan-
dardization panel and the titre-stratified specimens
from the country’s main serum bank. The regression
line chosen for standardization in this case was the
line of the best fit of the combined data, particularly in
the area around the negative/positive cut-off point
(equivocal range).
Standardization panel development and distribution
The standardization panel, which consisted of 150
plasma samples, reflected the immunity profile of a
general population group (negative or positive status
stemming either from disease or vaccination), since
the samples were collected from blood donors or re-
latives of hospitalized patients in Athens, Greece [33].
The standardization panel was designed to cover a
broad range of quantitative results and was developed
by combining samples with similar titres and/or by
diluting high-titre samples. Thus, of 150 samples, 40
consistently exhibited anti-HAV titres <0.01 IU/ml,
two exhibited titres ranging from >0.01 to 0.02 IU/
ml, while 108 samples exhibited titres >0.02 IU/ml,
as measured by the HAVAB 2.0 quantitative assay
on the AxSYM system (Abbott Laboratories,
Abbott Park, IL, USA) that was used by the reference
laboratory. The corresponding samples were classified
as ‘negative’, ‘ low-positive ’ (or ‘equivocal ’), and
‘positive’.
The panel (400-ml aliquots of each specimen) was
sent by courier post in a frozen state to all partici-
pating countries, where it was stored at x20 xC until
testing. Romania was the only country that did not
receive it in a frozen state.
Utilized serological assays
Participating countries employed five commercially
available enzyme-linked immunosorbent assay
(ELISA) kits to test for anti-HAV, as shown inTable 1.
Table 1. Type of standardization undertaken by participant countries by utilized enzyme immunoassay for the
determination of anti-HAV
Assay Manufacturer Standardization type Country
HAVAB 2.0 Abbott Main serum bank Romania
HAVAB 2.0 Abbott Quality assurance Israel
HAVAB Abbott Main serum bank Czech Republic
HAVAB Abbott Main serum bank Malta
HAVAB 2.0 (AxSYM) Abbott Back-standardization Germany
IMX HAVAB Abbott Back-standardization Spain
Enzygnost anti-HAV Dade Behring Main serum bank Finland
Enzygnost anti-HAV Dade Behring Main serum bank Lithuania
Enzygnost anti-HAV Dade Behring Main Serum Bank Luxembourg
ETI-AB-HAVK-3 DiaSorin Main serum bank Belgium
ETI-AB-HAVK-3 DiaSorin Main serum bank Ireland
ETI-AB-HAVK-3 DiaSorin Main serum bank Italy
ETI-AB-HAVK-3 DiaSorin Main serum bank Slovakia
ETI-AB-HAVK-3 DiaSorin Back-standardization UK
Abbott (Abbott Laboratories, Abbott Park, IL, USA); Dade Behring (Marburg, Germany) ; DiaSorin (Turin, Italy).
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The assays were performed and interpreted according
to the manufacturers’ instructions. Where possible,
antibody titres were quantified and expressed in IU/ml
based on the World Health Organisation (WHO)
International Standard.
Data analyses
Repeat testing of the standardization panel
Eight of the 16 participant countries tested the stan-
dardization panel twice: at the beginning of the proj-
ect to identify any potential assay problems and
during the testing of the main serum banks; the re-
maining countries (with the exception of the reference
laboratory, which as previously mentioned undertook
four rounds of testing), tested the panel only once
(Table 2). The paired results produced by testing the
panel twice with the same assay at each national lab-
oratory were compared by plotting the logarithms
(base 10) of the titres and drawing the slope through
the origin. The agreement between the first and sec-
ond round of testing of the standardization panel
was good both at the national and the reference
laboratories (data not shown), implying that the be-
tween-test variability was minimal. In all cases, the
results of the second set of tests were used for the
standardization of results since these measurements
were closer in time to the testing of the national main
serum banks.
Regression analysis – quantitative comparison of
standardized results
The results of the hepatitis A standardization panel
testing from each country were calibrated against the
results of the reference laboratory using a linear,
quadratic, or sigmoid model. Reported results with
concentrations outside the detection limits were as-
signed imputed titres ; in particular, concentrations
above the upper detection limit and below the lower
detection limit were doubled and halved, respectively
[34]. All values were log10-transformed prior to
analysis, with these results being plotted against the
reference centre’s results. Conversion factors were
derived by regression, assuming normal errors on the
logarithmic scale. The square of the multiple corre-
lation coefficient (R2) was calculated to quantify the
Table 2. Numbers of times the panel was tested, standardization equations, R2 values, and pre- and post-






Equivocal range (local units)
Pre-standardization Post-standardization






Finland 2 0.07x2+1.02xx0.36 0.99 0.010–0.020 0.008–0.013
Germany* 2 x022+ 140
1+ex(272+287x)
0.96 1.000 0.700–0.842
Ireland 2 0.05x2+1.17xx0.25 0.96 0.010–0.020 0.004–0.008
Israel# 1 0.10x2+1.10xx0.39 0.98 0.010–0.020 0.006–0.011
Italy 2 x0.07x2+0.97x+0.66 0.94 0.010–0.020 0.028–0.065
Lithuania 1 x239+ 147
1+ex(512+296x)
0.98 0.010–0.020 0.012–0.024
Luxembourg 1 0.04x2+0.99xx0.17 0.97 0.010–0.020 0.010–0.018
Malta 2 x041+ 139
1+ex(379+248x)
0.97 1.000 0.830–1.380
Romania 2 0.09x2+1.08xx0.37 0.98 0.010–0.020 0.007–0.011
Slovakia 2 x224+ 130
1+ex(1089+627x)
0.91 0.010–0.020 0.009–0.031
Spain* 1 0.19x+0.34 0.73 1.000 0.912–1.040
UK* 1 x0.09x2+0.25x+1.55 0.74 1.000–2.000 4.898–7.336
* Back-standardization.
# Quality assurance only (no main serum bank tested).
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proportion of variation between the testing and ref-
erence laboratory accounted for by the regression. An
R2 of at least 0.80 was considered to indicate that a
high percentage of variation was explained by the
model. The more parsimonious linear regression was
used unless a significantly better fit (assessed using an
F test) was obtained by the quadratic regression.
Sigmoid regression was applied in situations where it
provided a better fit of the data at the critical area
around the negative/positive cut-off point (the
equivocal range) [32].
Qualitative comparison of results
To assess the extent of qualitative agreement, the
standardized panel results from each country were
classified as negative, equivocal, or positive, by ap-
plying the cut-off values of the assay used by the ref-
erence laboratory (negative, <0.01 IU/ml; equivocal,
i.e. basic protection, >0.01–0.02 IU/ml; positive,
>0.02 IU/ml). These results were then tabulated
against the reference country’s qualitative results.
Non-standardized results were similarly tabulated
against the reference laboratory and the tables
were compared to investigate the effect of standardi-
zation.
RESULTS
Pairwise quantitative comparisons and regression
plots
The results of the testing of the standardization panel
obtained by each country as well as the regression
lines that were used in the standardizations are shown
in Figure 1. Figure 2 shows the corresponding results
generated from the three countries that undertook
back-standardization by testing a subset of samples
from their main serum banks. Four samples of the
panel were found to be consistent outliers among lab-
oratories and were, thereby, excluded from all analy-
ses. The provision of quantitative results by all
laboratories, wherever possible, limited the problem
of arbitrary results (i.e. ‘censored data’). No evidence
of significant influence of these censored data on the
standardization equations was identified in any of the
examined countries (data not shown).
The derived standardization equations and corre-
sponding R2 values for each country are given in
Table 2. Linear, quadratic and sigmoid equations
were used. The least amount of correlation accounted
for by the regression was observed in the United
Kingdom and Spain, where both undertook back-
standardization (with R2 values of 0.74 and 0.73, re-
spectively). For the remaining participant countries,
R2 values were all >0.80, with values ranging from
0.91 for Slovakia to 0.99 for Finland.
Table 2 also shows the equivocal range in local
units before and after standardization. For most
countries, the line of best fit passed through or very
close to the point of equivalence, hence minimizing
the impact of the process of standardization on
the final sero-profiles obtained from each country
(Figs 1, 2). However, the local assay overestimated
antibody titres in two instances (Italy, United
Kingdom), while the converse effect was observed in
three instances (Ireland, Israel, Germany) (Table 2,
Figs 1, 2).
Qualitative comparisons
To investigate further the qualitative improvement of
standardization, all measurements were compared
before and after the application of the reference lab-
oratory’s cut-off (i.e. pre- and post-standardization,
respectively) (Table 3). Most laboratories, especially
those that utilized the same or a similar assay as the
reference laboratory (namely, the Czech Republic,
Israel, Malta, Romania; Table 1), were almost in
complete agreement with Greece, the reference lab-
oratory, on the non-standardized results of negative
sera. The greatest discrepancies in the identification
of negative sera were noted in the three countries
that used the DiaSorin ETI-AB-HAVK-3 assay
(DiaSorin, Turin, Italy) : Belgium, Slovakia, and Italy
(with 17, 10, and five samples, classified as equivocal,
correspondingly). Standardization alleviated these
differences to a great extent, without affecting the
general good agreement in the classification of nega-
tive sera in the other countries. Only one discrepant
result, classified as negative in the reference labora-
tory and as positive in Lithuania, was noted; the
standardization procedure did not adjust for this local
observation.
DISCUSSION
International comparisons of serosurvey results that
provide the most accurate reflection of the immune
status of the population often constitute unattain-
able targets due to the lack of direct comparability
of obtained serological data; standardization is a
















































































































































































Fig. 1. Anti-HAV assay results of the standardization panel obtained by each country (y-axis) that undertook ordinary standardization plotted against the corresponding
results of the reference laboratory (Greece, x-axis) on the logarithmic (base 10) scale. Open squares denote outlier samples, while dotted lines show the equivocal ranges ; solid
























methodological approach that overcomes this limi-
tation by adjusting for laboratory and assay differ-
ences [32]. This methodology has been applied
successfully for various vaccine-preventable infec-
tions during the ESEN projects, i.e. : (i) measles,
mumps, rubella [16, 20] ; (ii) pertussis [17] ;
(iii) diphtheria [19]) ; (iv) VZV [18] ; and (v) HBV
[21].
The present collaborative work describes the de-
velopment of a standardization procedure that allows
for direct comparisons of HAV seroprevalence data
generated at 15 European laboratories. This aim was
achieved through the establishment of a standard
panel of 150 sera by a designated reference laboratory
and its subsequent testing by all participating coun-
tries by assay methods of their choice. The obtained
results were regressed against those of the reference
laboratory and standardization equations were de-
rived to provide the means to convert local (national)
results to common (reference laboratory) unit meas-
urements.
The standardization procedure was generally suc-
cessful, as reflected by the very high R2 values ranging
from 0.91 (for Slovakia) to 0.99 (for Finland), which
were obtained in all but two cases, namely Spain and
the United Kingdom (with R2 values of 0.73 and 0.74,
respectively, Table 2). Despite the fact that the chosen
regression models appeared to describe the Spanish,
but not the British, data reasonably well around the
critical positive/negative cut-off area (Fig. 2), the
variability that remained unexplained was un-
acceptably high for both these countries that under-
took back-standardization. Nevertheless, this reason,
by itself, does not explain satisfactorily these results,
since undertaking this type of analysis evidently did
not prevent Germany from obtaining a very high R2
value (0.96, Table 2). Thus, the most likely expla-
nation for these discrepant results seems to lie in the
utilized assays.
As shown in Table 1, Spain used IMx HAVAB
(Abbott), a test performed on an automated im-
munoassay system that was first introduced in
1988 and has since been substituted by the following
analysers : AxSYM in 1994, Prism in 1995, and
Architect in 1999 (all Abbott). Although both the
Spanish and the reference laboratory used micro-
particle enzyme immunoassays (MEIA) that are
based on the same fundamental principles, the results
they produce may still differ. This is not surprising
given that the IMx HAVAB assay was designed for
the qualitative determination of anti-HAV (positive
or negative status), in contrast to the assay used by the
reference laboratory that was designed for quantitat-
ive determinations of anti-HAV titres. It should
be noted, however, that when the standardization
panel was tested at the Spanish reference laboratory,
an agreement of 95.3% was obtained (data not
shown).
The United Kingdom used ETI-AB-HAVK-3, an-
other competitive binding ELISA assay for total anti-
body toHAV (DiaSorin). Interestingly, the qualitative
comparisons of the results obtained showed that the
greatest discrepancies in the negative sera prior to the
application of the reference laboratory’s cut-off (or, in
other words, prior to standardization) were noted in
the cases of Belgium, Slovakia, and Italy that all used
this same assay by DiaSorin (with 17, 10, and five
samples, correspondingly, classified as equivocal,
Table 3). However, these differences were alleviated to
a great extent by standardization.
This study demonstrated the practical usefulness of











































Fig. 2. Anti-HAV assay results of the standardization panel obtained by each country (y-axis) that undertook back-stan-
dardization plotted against the corresponding results of the reference laboratory (Greece, x-axis) on the logarithmic (base 10)
scale. Open squares denote outlier samples, while dotted lines show the equivocal ranges ; solid lines represent the regression
models.
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directly compared. To our knowledge, this is the first
time that such an international seroepidemiological
project has taken place for HAV. The results are ex-
pected to contribute to the evaluation and potential
improvement of the currently employed immuniz-
ation strategies for hepatitis in Europe.
ACKNOWLEDGEMENTS
This work was funded by a grant from DG X11
of the European Union under contract QLK2-CT-
2000-00542 (concerted action). Further sources of
funding include CRP-Santé (Luxembourg) and ISCIII
Table 3. Qualitative comparison of national ELISA results pre- and post-
standardization vs. the respective results obtained by the reference laboratory
(non-standardized results are given in parentheses)
Country
(% agreement)







Belgium (94.5%) Positive 104 (104) 2 (2) 0 (0)
Equivocal 0 (0) 0 (0) 6 (17)
Negative 0 (0) 0 (0) 34 (23)
Czech Republic
(99.3%)
Positive 104 (104) 0 (1) 0 (0)
Equivocal 0 (0) 1 (0) 0 (0)
Negative 0 (0) 1 (1) 40 (40)
Finland (98.6%) Positive 104 (103) 2 (0) 0 (0)
Equivocal 0 (1) 0 (2) 0 (0)
Negative 0 (0) 0 (0) 40 (40)
Ireland (99.2%) Positive 89 (88) 0 (0) 0 (0)
Equivocal 0 (1) 2 (0) 1 (0)
Negative 0 (0) 0 (2) 39 (40)
Israel (98.6%) Positive 103 (100) 1 (0) 0 (0)
Equivocal 0 (3) 1 (2) 0 (0)
Negative 1 (1) 0 (0) 40 (40)
Italy (96.6%) Positive 100 (104) 0 (1) 0 (0)
Equivocal 4 (0) 1 (1) 0 (5)
Negative 0 (0) 1 (0) 40 (35)
Lithuania (97.9%) Positive 103 (104) 1 (1) 1 (1)
Equivocal 1 (0) 1 (1) 0 (1)
Negative 0 (0) 0 (0) 38 (37)
Luxembourg (98.6%) Positive 104 (104) 1 (1) 0 (0)
Equivocal 0 (0) 1 (1) 1 (1)
Negative 0 (0) 0 (0) 39 (39)
Malta (96.5%) Positive 98 (101) 0 (1) 0 (0)
Equivocal 4 (0) 2 (0) 0 (0)
Negative 1 (2) 0 (1) 39 (39)
Romania (97.2%) Positive 101 (101) 1 (0) 0 (0)
Equivocal 0 (0) 1 (2) 2 (0)
Negative 1 (1) 0 (0) 37 (39)
Slovakia (95.2%) Positive 98 (104) 0 (1) 0 (0)
Equivocal 5 (0) 2 (1) 1 (10)
Negative 1 (0) 0 (0) 39 (30)
Four of the 150 samples of the standardization panel were excluded from all
analyses as outliers. Moreover, four countries did not test all these 146 samples of
the panel ; in particular : Ireland did not test 15 positive samples, Lithuania did not
test one negative, Malta did not test one positive and one negative, and Romania
did not test two positive and one negative samples.
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